Ellington Management Group’s Alder Biopharmaceuticals ALDR Stock Holding History

Ellington Management Group’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-11,200	Closed	-$142K	–	998
2018 Q1	$142K	Buy	+11,200	New	+$162K	0.01%	765
2017 Q4	–	Sell	-17,700	Closed	-$217K	–	909
2017 Q3	$217K	Buy	+17,700	New	+$185K	0.04%	502
2015 Q3	–	Sell	-7,610	Closed	-$403K	–	980
2015 Q2	$403K	Buy	+7,610	New	+$277K	0.1%	319
2015 Q1	–	Sell	-15,200	Closed	-$442K	–	884
2014 Q4	$442K	Buy	+15,200	New	+$273K	0.15%	232

Other funds holding ALDR

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ellington Management Group's ALDR Position: Q2 2018 in Review

Ellington Management Group sold out of Alder Biopharmaceuticals (ALDR) in Q2 2018, closing a stake of 11,200 shares — an estimated $142K sold.

Ellington Management Group first reported a position in ALDR in Q4 2014 and held it in 4 quarters. The position peaked at $442K in Q4 2014. 139 funds tracked by Wall St. Rank hold ALDR as of Q2 2018.

Ellington Management Group reported no remaining Alder Biopharmaceuticals position as of Q2 2018 after selling out during the quarter.
Ellington Management Group sold 11,200 Alder Biopharmaceuticals shares in Q2 2018, an estimated $142K.
Ellington Management Group first reported a position in Alder Biopharmaceuticals in Q4 2014 and held it in 4 quarters.
Ellington Management Group's Alder Biopharmaceuticals position peaked at $442K in Q4 2014.
139 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2018.

Based on Ellington Management Group's 13F filing for Q2 2018, filed 14 Aug 2018.